Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent Long-term Complications After Pediatric Heart Transplantation

Trial Profile

Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent Long-term Complications After Pediatric Heart Transplantation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Heart transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TEAMMATE
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 04 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top